Does DURVALUMAB Cause Hypertransaminasaemia? 15 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 15 reports of Hypertransaminasaemia have been filed in association with DURVALUMAB (IMFINZI). This represents 0.1% of all adverse event reports for DURVALUMAB.
15
Reports of Hypertransaminasaemia with DURVALUMAB
0.1%
of all DURVALUMAB reports
0
Deaths
10
Hospitalizations
How Dangerous Is Hypertransaminasaemia From DURVALUMAB?
Of the 15 reports, 10 (66.7%) required hospitalization.
Is Hypertransaminasaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DURVALUMAB. However, 15 reports have been filed with the FAERS database.
What Other Side Effects Does DURVALUMAB Cause?
Death (2,817)
Malignant neoplasm progression (1,330)
Pneumonitis (827)
Radiation pneumonitis (786)
Pyrexia (573)
Diarrhoea (530)
Pneumonia (453)
Dyspnoea (444)
Interstitial lung disease (430)
Off label use (395)
What Other Drugs Cause Hypertransaminasaemia?
METHOTREXATE (436)
ACETAMINOPHEN (326)
PACLITAXEL (318)
CARBOPLATIN (304)
PEMBROLIZUMAB (231)
ATORVASTATIN (207)
CYCLOPHOSPHAMIDE (202)
PREDNISONE (198)
GEMCITABINE (196)
DEXAMETHASONE (169)
Which DURVALUMAB Alternatives Have Lower Hypertransaminasaemia Risk?
DURVALUMAB vs DUTASTERIDE
DURVALUMAB vs DUTASTERIDE\TAMSULOSIN
DURVALUMAB vs DUVELISIB
DURVALUMAB vs DYDROGESTERONE
DURVALUMAB vs EBASTINE